📣 New in @drugsincontext.bsky.social
Patterns of treatment and outcomes of patients with metastatic HER2-low #breastcancer treated with CDK4/6 inhibitors and #hormonetherapy
Sottotetti et al.
#drugsincontext #oncology #medsky #realworldstudy
www.drugsincontext.com/patterns-of-...
Patterns of treatment and outcomes of patients with metastatic HER2-low #breastcancer treated with CDK4/6 inhibitors and #hormonetherapy
Sottotetti et al.
#drugsincontext #oncology #medsky #realworldstudy
www.drugsincontext.com/patterns-of-...
Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy - Drugs in Context
This study aims to investigate, through a retrospective approach and in a real-world setting, the activity and effectiveness of CDK4/6i as first-line or second-line treatment in a HR+/HER2-low populat...
www.drugsincontext.com
May 7, 2025 at 3:13 PM
Everybody can reply
#vaccines #COVID19 #Novavax #realworldevidence #JN1adaptedCOVID19vaccine #COVID19vaccine #SHIELDUtahstudy #Novavaxvaccine #Pfizer #BioNTech #mRNA20242025vaccine #realworldstudy #nonmRNACOVID19vaccine #proteinbasedCOVID19vaccine #COVID19vaccination
pharmatimes.com/news/novavax...
pharmatimes.com/news/novavax...
Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine - PharmaTimes
The SHIELD-Utah study compared Novavax’s vaccine to the Pfizer/BioNTech mRNA 2024-2025 vaccine
pharmatimes.com
April 29, 2025 at 2:06 PM
Everybody can reply